GW Pharmaceuticals Plc has raised $300 million in a secondary offering on the US Nasdaq, providing it with capital to commercialise its recently approved cannabinoid medicine Epidiolex for the treatment of seizures associated with the childhood epilepsies, Lennox-Gastaut syndrome and Dravet syndrome.
Epidiolex was approved by the US Food and Drug Administration on 25 June. The medicine is currently under review at the European Medicines Agency with a decision expected in the first quarter of 2019.